Gill, Michael
Bristol-Myers Squibb (United States)
3 papers on CoChat
Most cited papers
- Verified
Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA 1 ) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases
Cheng, P. T. W., Kaltenbach, R. F., Zhang, H., Shi, J., Tao, S., Li, J., Kennedy, L. J., Walker, S. J., Shi, Y., Wang, Y., et al. (2021) · Journal of Medicinal Chemistry
Sphingolipid Metabolism and SignalingInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Cited by 61
- Verified
Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: contrasts with BMS-986234 and BMS-986278
Gill, M. W., Murphy, B. J., Cheng, P. T. W., Sivaraman, L., Davis, M., & Lehman-McKeeman, L. (2022) · Toxicology and Applied Pharmacology
Drug-Induced Hepatotoxicity and ProtectionDrug Transport and Resistance Mechanisms
Cited by 41
- Verified
Structure dependence and species sensitivity of in vivo hepatobiliary toxicity with lysophosphatidic acid receptor 1 (LPA1) antagonists
Sivaraman, L., Gill, M., Nelson, D. M., & Chadwick, K. D. (2022) · Toxicology and Applied Pharmacology
Drug-Induced Hepatotoxicity and ProtectionAnimal testing and alternatives
Cited by 17
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free